We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Liquid Biopsy Test Predicts Early Disease Progression and Survival in Advanced Breast Cancer Patients

By LabMedica International staff writers
Posted on 14 Jun 2023
Print article
Image: Study co-author Mary Jo Fackler, Ph.D., analyzes patient plasma samples (Photo courtesy of Madison Pleas)
Image: Study co-author Mary Jo Fackler, Ph.D., analyzes patient plasma samples (Photo courtesy of Madison Pleas)

There is a pressing need for predictive clinical biomarkers to identify early disease progression in women with metastatic breast cancer, considering its heterogeneous nature. Such biomarkers could aid oncologists in reducing the adverse impacts on patients’ quality of life from drug combinations by optimizing the deployment of available and effective therapies. Now, a novel, automated liquid biopsy test can predict early disease progression and potential survival in patients with metastatic breast cancer in one month after commencing treatment.

The Liquid Biopsy for Breast Cancer Methylation (LBx-BCM) assay, currently under development by researchers at the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA), is a prototype for research use only at this stage. The assay is compatible with the GeneXpert molecular testing platform and requires less than 15 minutes of hands-on time by a lab technician. The assay is capable of detecting methylation in nine genes, which are known to be altered in the four breast cancer subtypes: AKR1B1, TM6SF1, ZNF671, TMEFF2, COL6A2, HIST1H3C, RASGRF2, HOXB4, and RASSF1, in under five hours. Methylation, a chemical tag associated with cancer development and progression, can deactivate tumor suppressor genes.

In a study, the LBx-BCM assay identified cancer DNA in one or more of nine commonly altered genes in breast cancers from blood samples of women undergoing breast cancer treatment. Patients with high cumulative methylation levels four weeks into treatment experienced significantly shorter progression-free survival periods (time during which the disease does not advance) and worse overall survival compared to those with low cumulative methylation. Researchers used the week-four cumulative methylation levels to develop and evaluate a new model for predicting disease progression as early as three months after initiating treatment. Future research objectives include studying weekly methylation patterns after starting treatment to determine the best time for measuring cumulative methylation, and refining and validating the model in similar patient populations and those with early-stage disease.

“It looks promising that we can detect methylation in the first four weeks of treatment,” said lead study author Kala Visvanathan, M.D., M.H.S., director of the Cancer Genetics and Prevention Service at the Johns Hopkins Kimmel Cancer Center. “Currently, we wait until we see symptomatic or clinical changes, usually within three months, before adjusting treatments. If we could detect changes earlier, we could adjust treatments earlier, if necessary, with the goal of achieving better clinical outcomes and prolonging survival.”

Related Links:
Johns Hopkins Medicine 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Human Placenta DNA
Human Placenta DNA
New
Hepatitis B Assay
Monolisa HBs Ag ULTRA Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.